电子低能光子术中放疗剂量学形式化的临床意义
本研究用电离室测量比较 INTRABEAM 与 Xoft Axxent 乳腺术中放疗的剂量学算法。名义处方 20 Gy 时,INTRABEAM 施源器表面按 CQ 法为 25.2 至 31.7 Gy,Zeiss V4.0 法低 7% 至 10%,且剂量随球囊施源器尺寸变化。Xoft Axxent 在 1 cm 深度剂量略低于 INTRABEAM。
要点
- TARGIT 方案下 INTRABEAM 实际剂量显著高于处方 20 Gy
- 剂量学算法选择使结果相差 7% 至 10%,需统一报告形式
- Xoft Axxent 与 INTRABEAM 剂量存在差异,跨设备比较需谨慎
核心结论
- TARGIT 乳腺方案中 INTRABEAM 递送剂量显著大于处方 20 Gy,并取决于所用球囊施源器尺寸。
- Xoft Axxent 乳腺术中放疗剂量低于 TARGIT INTRABEAM,可能影响两种设备的临床结局比较。
研究设计与样本
- 用 INTRABEAM 电离室测量数据,分别按 Zeiss V4.0 法、蒙特卡罗计算腔室转换因子(CQ 法)和 TARGIT 方案公式计算吸收剂量。
- Xoft Axxent 剂量由电离室测量按 Zeiss V4.0 法确定,并用美国医学物理学家协会 TG-43 形式化计算。
主要发现
- 名义 TARGIT 处方 20 Gy 时,CQ 法下 INTRABEAM 施源器表面剂量在最大(5 cm)与最小(1.5 cm)直径施源器分别为 25.2 Gy 与 31.7 Gy。
- Zeiss V4.0 法结果比 CQ 法低 7% 至 10%(23.2 至 28.6 Gy)。
- 1 cm 深度处 CQ 法与 Zeiss V4.0 法吸收剂量也大于 TARGIT 法预测值。
- Xoft Axxent 在表面剂量 20 Gy 时,1 cm 深度剂量较 INTRABEAM 略低(与 CQ 法相比低 3% 至 7%)。
- 3 cm 施源器为例外,Xoft 剂量明显更低(31%)。
关键数值与推荐
- TARGIT 乳腺方案名义处方剂量为 20 Gy。
- CQ 法下 INTRABEAM 表面剂量:5 cm 施源器 25.2 Gy,1.5 cm 施源器 31.7 Gy。
- Zeiss V4.0 法结果较 CQ 法低 7% 至 10%,对应 23.2 至 28.6 Gy。
- Xoft Axxent 1 cm 深度剂量较 INTRABEAM CQ 法低 3% 至 7%,3 cm 施源器低 31%。
临床怎么用
- 乳腺术中放疗应明确并统一报告所用剂量学形式化方法,避免处方与实际剂量偏差被忽视。
- 比较 INTRABEAM 与 Xoft Axxent 的临床结局研究时,需考虑两者剂量学差异及施源器尺寸影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraoperative radiation therapy (IORT) using the INTRABEAM, a miniature x-ray source, has shown to be effective in treating breast cancer. However, recent investigations have suggested a significant deviation between the reported and delivered doses. In this work, the dose delivered by INTRABEAM in the TARGIT breast protocol was investigated, along with the dose from the Xoft Axxent, another source used in breast IORT. METHODS AND MATERIALS: The absorbed dose from the INTRABEAM was determined from ionization chamber measurements using: (a) the manufacturer-recommended formula (Zeiss V4.0 method), (b) a Monte Carlo calculated chamber conversion factor (CQ method), and (c) the formula consistent with the TARGIT breast protocol (TARGIT method). The dose from the Xoft Axxent was determined from ionization chamber measurements using the Zeiss V4.0 method and calculated using the American Association of Physicists in Medicine TG-43 formalism. RESULTS: For a nominal TARGIT prescription of 20 Gy, the dose at the INTRABEAM applicator surface ranged from 25.2 to 31.7 Gy according to the CQ method for the largest (5 cm) and smallest (1.5 cm) diameter applicator, respectively. The Zeiss V4.0 method results were 7% to 10% lower (23.2 to 28.6 Gy). At 1 cm depth, the CQ and Zeiss V4.0 absorbed doses were also larger than those predicted by the TARGIT method. The dose at 1 cm depth from the Xoft Axxent for a surface dose of 20 Gy was slightly less than INTRABEAM (3%-7% compared with CQ method). An exception was for the 3 cm applicator, where the Xoft dose was appreciably lower (31%). CONCLUSIONS: The doses delivered in the TARGIT breast protocol with INTRABEAM were significantly greater than the prescribed 20 Gy and depended on the size of spherical applicator used. Breast IORT treatments with the Xoft Axxent received less dose compared with TARGIT INTRABEAM, which could have implications for studies comparing clinical outcomes between the 2 devices.
引用
- Watson PGF, Popovic M, Liang L, et al. Clinical Implication of Dosimetry Formalisms for Electronic Low-Energy Photon Intraoperative Radiation Therapy. Pract Radiat Oncol. 2020. PMID: 32795615. doi:10.1016/j.prro.2020.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。